Zoetis Inc. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
Zoetis Inc. (ZTS) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax of -$19.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax · last filed 2026-02-12
- Zoetis Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2025 was -$19.00M, a 575.00% decline from fiscal 2024.
- Zoetis Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2024 was $4.00M.
- Zoetis Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2023 was -$5.00M, a 105.81% decline from fiscal 2022.
- Zoetis Inc. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2022 was $86.00M, a 352.63% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 12 month |
|---|---|
| 2025-12-31 | -$19.00M 10-K · filed 2026-02-12 |
| 2024-12-31 | $4.00M 10-K · filed 2026-02-12 |
| 2023-12-31 | -$5.00M 10-K · filed 2026-02-12 |
| 2022-12-31 | $86.00M 10-K · filed 2025-02-13 |
| 2021-12-31 | $19.00M 10-K · filed 2024-02-13 |
| 2020-12-31 | -$15.00M 10-K · filed 2023-02-14 |
| 2019-12-31 | $4.00M 10-K · filed 2022-02-15 |
| 2018-12-31 | -$1.00M 10-K · filed 2021-02-16 |
| 2017-12-31 | -$11.00M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |